Law360, New York (April 11, 2008, 12:00 AM ET) -- Genzyme Corp. has voluntarily recalled 100,000 vials of Thymoglobulin, a drug widely used during kidney transplants, even though most of the batches have already been used without any complaints or adverse reactions.
The company recalled the batches after federal regulators noticed vials of the drug appeared cloudier than normal during a routine quality control inspection, a spokeswoman for Genzyme said Friday.
The three recalled lots of the drug, manufactured in 2007, do not pose a health risk to patients and the company does not expect to...
Genzyme Recalls Murky Batches Of Transplant Drug
To view the full article, take a free trial now.
